On the one hand, it is impacting their product marketing and education of medical professionals which is, in turn, impacting patient access in the UK. This is why GW have chosen to invest more in other countries that have less restrictive medical cannabis regulations. On the other side, it's current status in ...
read more here
Delivered by @can_nab_is
No comments:
Post a Comment